Share Name Share Symbol Market Type Share ISIN Share Description
Phynova Group LSE:PYN London Ordinary Share GB00B0YBCM49 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.375p 0.00p 0.00p - - - 0 06:40:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 0.44

Phynova Share Discussion Threads

Showing 1 to 19 of 25 messages
Chat Pages: 1
Cancellation notice issued this morning as planned.
best stay out IMO it's delisting (24.8.09) nia dyor
its going to 5p end of next week
Well - we're now down to a MC of around £600k. Recent share placing at 6p (with warrants at 10p) - currently 2.375p! Will those who took up the placing be regretting things ??
Phynova Group PLC said preliminary data from the phase I/II trials of its lead drug candidate PYN17, for treating chronic hepatitis C, successfully confirms its safety and tolerability. The company said the results show that PYN17 was well tolerated, with a low level of relatively minor adverse events identical to those seen with a placebo. The developer of drugs derived from Chinese botanical medicines said it expects to commence the phase IIb study for PYN17 in the first half of 2008.
Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, today announces that its Business Development Director, Dr Tony Mills, will provide an update on its plant-derived antibacterial PYN6 at the natural products conference "Natural Products in Drug Discovery and Development" at the Holiday Inn, Munich City Centre on Tuesday, 4 December. Results from pre-clinical work conducted by Phynova in collaboration with the University of East London have demonstrated a high degree of bacterial inhibition against 30 common strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from London's teaching hospitals. Inhibition was demonstrated against all of the strains of MRSA that were tested, using levels of PYN6 that were some tenfold less than that typically needed to achieve inhibition with mupirocin, the topical antibiotic currently routinely used for treatment of skin infections involving MRSA. Furthermore resistance to PYN6 has not been observed even after prolonged culture of numerous MRSA strains with PYN6. PYN6 has also shown significant activity against the Propionibacterium acnes organism which causes acne. Phynova is conducting formulation studies to develop a topical gel, cream or ointment containing PYN6 as active ingredient and is in active discussions with several companies in the dermatological sector regarding the future development and commercialisation of PYN6. Robert Miller, Phynova's CEO, said: "Gaining access to potentially valuable new drug opportunities such as PYN6 was an important part of the rationale for our cooperation with our Chinese partner Botanic Century. We are delighted that the extensive preclinical work that we have carried out this year has confirmed its promise as a potential treatment for MRSA, the devastating bacterial infection that has become such a problem in the UK. An additional key part of our commercial strategy is to offer a proportion of our drug candidates as in licensing opportunities to the pharma industry so we are also very pleased with the interest that we are attracting from potential partners."
highly undervalued company.. one drug for treating hepatitis C already in phase 11 trials in america..another two drug candidates will be in trials by end of year. HCV(hep c)drug may be introduced before it is accepted in the US and talks are being held in Brazil and Russia already.
Big deal signed for Phynova Phynova teams up with Hong Kong By Mark Kleinman in Hong Kong Last Updated: 1:22am GMT 06/02/2007 Phynova, the Aim-listed company searching for cancer cures based on plant extracts, will today announce a collaboration with a Hong Kong organisation affiliated to the city's Jockey Club. The company, which marks its first anniversary as a UK-listed company this month, is expected to announce in a statement to the London Stock Exchange that it has signed a deal to work with the government-funded Jockey Club Institute of Chinese Medicine on the development of a series of new drugs. The company is relatively small in market value - £13m at yesterday's close - but executives are understood to believe it could be worth ten times that amount within a few years. Last week, Phynova appointed entrepreneur Karl Watkin as its chairman. Mr Watkin has been involved with several listed companies including D1 Oils, the biodiesel producer, China Goldmines and Dermasalve, a developer of retail dermatology products. Phynova's agreement in Hong Kong will mark the latest exposure of UK investors to the burgeoning Traditional Chinese Medicine (TCM) sector. --
29 January 2007 Phynova's oriental promise "It's been a busy year," says chief executive Robert Miller. Indeed, since Phynova joined Aim in February 2006 it has won US approval to start clinical studies of PYN17, for hepatitis C symptoms, snapped up a 45 per cent stake in Chinese company Botanic Century and established a Chinese subsidiary. In addition, it has also licensed in PYN22, for fatty liver disease and obesity, and PYN6, an antibacterial agent. The company is developing drugs from Chinese botanical medicines and plans to commercialise them in the western and Chinese markets. Western pharmaceutical companies are becoming more interested in Chinese medicines – AstraZeneca has built a research and development facility in China - and US regulators recently approved Medigene's botanical drug for genital warts. The hepatitis C market will be worth $9bn in annual sales by 2010 and China is the biggest market. Mr Miller admits that success in China depends on building key relationships with companies and regulators. But former deputy director of the Chinese regulator, Dr Ren Dequen, recently became Phynova's co-chairman, and the stake in Botanic Century gives it a foothold in China. Mr Miller is also keen to sign licensing deals as early as possible The shares have been disappointing since the flotation and the portfolio is early stage. But, with enough cash until 2008, they look speculative good value.
w r
Phynova Appointment of Chairman RNS Number:2620Q Phynova Group PLC 29 January 2007 For Immediate Release 29 January 2007 PHYNOVA GROUP PLC Appointment of Karl Watkin as Chairman Phynova Group PLC ("Phynova" or the "Group") (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce the appointment of Karl E Watkin MBE as Chairman. Karl, appointed as Non-Executive Director on 14 December 2006, replaces John Pool who will continue to act as a Non-Executive Director on the Board. Both appointments are effective immediately. Karl brings to the role of Chairman over 25 years experience working in China, a market critical to Phynova's business strategy and extensive public company experience. Until earlier this month, Karl was Chairman of D1 Oils plc, a UK-based global producer of biodiesel, for which he is the founder and received an MBE for his services to UK exports in 1993. He will remain on the Board as a Non-Executive Director of D1 Oils. Other current directorships include Non-Executive Director of China Goldmines plc, a gold resource company with a direct interest in a gold mining project in the province of Hunan China. Karl also brings valuable expertise gained from the healthcare sector via Dermasalve Sciences plc, a developer of retail dermatology products, which he created in 2004, floated in January 2006 and currently serves as a Non-Executive Director. John Pool has served as Chairman since February 2005, in which time Phynova has progressed from an early stage private company to an acquisitive publicly listed company. Robert Miller, Chief Executive of Phynova, commented: "We are delighted that Karl has become Chairman of the Board. He brings a great deal of public company and Chinese experience which will be of great value to the Company as it progresses through clinical trials this year and further develops its Chinese operations. John is an invaluable asset to the Company and I wish to thank him for all his hard work in moving the Company forward. We are pleased that the Company will retain his expertise as Non-Executive Director." Karl Watkin, Chairman of Phynova, commented: "With the recent acceptance of its IND application to commence clinical trials of PYN17 for Hepatitis C and the acquisition of Botanical Century in China last year, Phynova is gaining momentum in both its drug pipeline and expansion into the Chinese market. As such, it is a very exciting time to be taking up the role of Chairman. I hope that through my experience in China, I will be able to build on this momentum."
Phynova applies for patents for Chinese herb drugs for obesity, hepatitis C LONDON (AFX) - Phynova Group PLC, which develops pharmaceuticals from Chinese medicines, said it has filed patent applications for its PYN-22 drug for obesity and its PYN-18 drug for hepatitis C. And it said it has signed a letter of intent with a clinical research organisation to start Phase IIb trials of its lead development product, PYN-17 for hepatitis C. Chief executive Robert Miller said the company has also strengthened its management team by appointing Stephen Marshall as chief operating officer and David Galloway as chief medical officer. lam/jm
Phynova Group PLC 16 May 2006 For Immediate Release 16 May 2006 Phynova Group PLC Interim Results For the Six Months Ended 31 March 2006 Phynova Group PLC ('Phynova' or the 'Group') (AIM : PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce maiden interim results for the six months ended 31 March 2006. Key Points: •Successful flotation on AIM in February 2006 having raised £3.65 million via a placing •In-license of PYN22, drug candidate targeting obesity •Positive outcome from pre-clinical testing on PYN18, drug candidate targeting the Hepatitis C Virus (HCV) • Additional source of future revenues from a collaboration agreement with WellGen, Inc. for development of Phynova compounds as nutrigenomic ingredients for functional foods John Pool, Chairman of Phynova, commented: 'Our successful flotation is a major stride forward for the Company enabling us to concentrate fully on the development of our product pipeline. We believe that the following six months will be an equally exciting period for the Company in terms of its development and we look forward to updating shareholders on our progress.' For further information, please contact: Phynova Group PLC Robert Miller, Chief Executive 01865 784880 Nabarro Wells Marc Cramsie, Director 020 7710 7400 Buchanan Communications Tim Anderson/Isabel Podda/Amy Rajendran 020 7466 5000 Chairman's and Chief Executive's Review We are delighted that our introduction to AIM on 27 February 2006 saw the Company advance its development through a pre-IPO placement, which raised £3.65 million before expenses. This has allowed Phynova to concentrate on the development of the most advanced products in its pipeline with a view to moving them into clinical trials within twelve months. Strategy We have established a business model which seeks to reduce the risks, the high cost and the time taken to develop pharmaceuticals by selecting drug candidates which are not only derived from existing medicines with proven safety and efficacy in clinical use in China but also which target large therapeutic markets in the West where current therapies are either inadequate or non-existent. We aim to license our intellectual property to major pharmaceutical companies in return for revenue in the form of upfront payments, milestone payments and royalties. We have identified a number of drug candidates in the fields of anti-virals, anto-microbials, anti-inflammatories and oncology and are currently focusing on the rapid development of six of these. o PYN17 for relief of the symptoms of chronic hepatitis C (CHC) o PYN18 for hepatitis C virus (HCV) o PYN22 for obesity o PYN7 for cancer o PYN6 for antibiotic-resistant bacteria o PYN5 to treat respiratory tract infections Portfolio Update Since our admission to AIM we have continued to work on the development of our intellectual property both existing and new. In April we were pleased to announce the positive outcome from third party testing on PYN18, a novel anti-viral discovered by Phynova's scientists has shown definite in vitro activity against the hepatitis C virus. Since announcing these results we have seen significant interest regarding potential partnerships to drive PYN18 through clinical development. HCV has infected more than 200 million people worldwide and current therapies are often ineffective with negative side-effects. We are also pleased to announce that the Company has entered into a Collaboration Agreement with WellGen, Inc., a life sciences company using nutrigenomics to discover and develop ingredients for functional foods. This agreement gives us an exciting opportunity to generate additional revenues from our research activities. Under the terms of the agreement Phynova will supply WellGen with sample compounds that demonstrate anti-inflammatory activity from its existing pipeline, then work to develop these as functional food ingredients. If successful, royalties will provide a revenue stream in addition to those from our core business. The size of the functional foods market, according to, is expected to grow to $167 billion globally by 2010. During the period, good progress has made on the other products in your Company's pipeline, including the in-licensing of a promising new drug candidate (PYN22) for the anti-obesity market which is estimated to be worth $5 billion. Financial Review In the six months ended 31 March 2006, Phynova recorded a pre-tax loss of £597,000, which is in line with expectations. Cash outflow before financing was £609,000 reflecting the loss for the period. Our cash position remains strong and at 31 March 2006 was £2.9 million following our successful pre-IPO fund raising. We are pleased to confirm that we continue to make good use of cash resources and that we remain firmly committed to our budget. Summary and Prospects The progression of our product portfolio has been very encouraging. PYN18 has clearly demonstrated its potential in all initial testing and we anticipate taking this candidate into clinical development as rapidly as possible. Our pre-clinical development program is very active and several of our drug candidates are the subject of on-going screening work by third parties and we look forward to announcing the results in due course. We would like to thank all our shareholders, both existing and new, for their support. We look forward to the next six months in which we will continue to make significant strides in the further development of our product pipeline. John Pool Robert Miller Chairman Chief Executive Officer PHYNOVA GROUP PLC CONSOLIDATED SUMMARISED PROFIT AND LOSS ACCOUNT For the six months ended 31 March 2006 6 months 6 months 15 months Ended Ended Ended 31 March 2006 31 March 2005 30 September 2005 Note Unaudited Unaudited Audited £'000 £'000 £'000 Turnover - - - Cost of sales - research and development (160) (111) (243) Gross Loss (160) (111) (243) Administrative expenses Administrative expenses (315) (139) (364) Aim Listing expenses (130) - - Total administrative expenses (445) (139) (364) Operating loss (605) (250) (607) Interest receivable 8 - - Loss on ordinary activities before and after taxation (597) (250) (607) Basic and diluted loss per share 2 (6.5p) (3.7p) (8.7)p All amounts relate to continuing operations. There were no recognised gains or losses other than the loss for the financial period. PHYNOVA GROUP PLC CONSOLIDATED SUMMARISED BALANCE SHEET AS AT 31 MARCH 2006 At At At 31 March 2006 31 March 2005 30 September 2005 Note Unaudited Unaudited Audited £'000 £'000 £'000 Fixed assets Tangible assets 3 2 2 Current assets Debtors 215 58 204 Cash at bank and in hand 2933 105 29 3148 163 233 Creditors: amounts falling 217 224 217 due within one year Net current assets/(liabilities) 2931 (61) 16 Total assets less current liabilities 2934 (59) 18 Provision for liabilities and charges (236) (94) (236) Net assets/ (liabilities) 2698 (153) (218) Capital and reserves Called up share capital 148 71 76 Share premium account 3860 226 419 Merger difference reserve 642 642 642 Profit and loss account (1952) (1092) (1355) Shareholders' funds/(deficit) 3 2698 (153) (218) PHYNOVA GROUP PLC CONSOLIDATED SUMMARISED CASH FLOW STATEMENT AS AT 31 MARCH 2006 6 months 6 months 15 months Ended Ended Ended 31 March 31 March 30 2006 2005 September 2005 Note Unaudited Unaudited Audited £'000 £'000 £'000 Net cash (outflow) from operating activities 4 (615) (178) (453) Returns on investments and servicing of - - finance Interest received 8 - - Net cash inflow from returns on investments and servicing of finance 8 - - Capital expenditure and financial investment Purchase of tangible fixed assets (2) - (1) Net cash (outflow) from capital expenditure and financial investment (2) - (1) Cash outflow before financing (609) (178) (454) Financing Issue of ordinary share capital 3733 231 429 Share Issue expenses (220) - - Net cash inflow from financing 3513 231 429 Increase in cash 2904 53 (25) NOTES TO THE INTERIM STATEMENT For the six months ended 31 March 2006 1. BASIS OF PREPARATION The consolidated interim financial statements have been prepared in accordance with applicable accounting standards and under the historical cost convention. The principal accounting policies of the group have remained unchanged from those set out in Phynova Group plc 2005 financial statements except for the adoption of FRS21 'Events after the balance sheet date' and FRS 25 'Financial instruments: Disclosures and Presentation'. 2. LOSS PER SHARE The calculation of the basic and diluted loss per share is based on the loss on ordinary activities after tax and on the weighted average number of ordinary shares in issue during the period. The loss and weighted average number of shares used in the calculations are set out below: Basic and diluted loss Loss Weighted average Loss per share per share £'000 number of shares pence Six months ended 31st March 2006 (597) 9,232,227 (6.5) Six months ended 31st March 2005 (250) 6,684,505 (3.7) 15 months ended 30th September 2005 (607) 6,952,913 (8.7) 3. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS/ (DEFICIT) 6 months 6 months 15 months Ended Ended Ended 31 March 2006 31 March 2005 30 September 2005 Unaudited Unaudited Audited £'000 £'000 £'000 Loss for the financial period (597) (250) (607) Issue of ordinary share capital 72 5 10 Premium on shares issued during the period net of expenses 3441 226 419 Net increase (decrease) in shareholders' funds/(deficit) 2916 (19) (178) Shareholders' funds/ (deficit) at beginning of period (218) (134) (40) Shareholders' funds/ (deficit) at end of period 2698 (153) (218) NOTES TO THE INTERIM STATEMENT continued For the six months ended 31 March 2006 4. NET CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES 6 months 6 months 15 months Ended Ended Ended 31March 2006 31March 2005 30 September 2005 Unaudited Unaudited Audited £'000 £'000 £'000 Operating (loss) (605) (250) (607) Depreciation 1 1 2 (increase) in debtors (11) (53) (199) Increase in creditors - 30 115 Increase in provisions - 94 236 Net cash (outflow) from operating activities (615) (178) (453) 5. RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS 6 months 6 months 15 months Ended Ended Ended 31 March 2006 31 March 2005 30 September 2005 Unaudited Unaudited Audited £'000 £'000 £'000 Increase / (decrease) in cash in the period 2904 53 (25) Movement in net funds 2904 53 (25) Opening net funds 29 52 54 Closing net funds 2933 105 29 6. FINANCIAL COMPARATIVES The comparatives for the 15 month period ended 30 September 2005 are not the Company's full statutory accounts for that period. A copy of the statutory accounts for that period was delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain a statement under section 237(2)-(3) of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Shares in newly-listed Phynova fell 12.5p to 120p on their second day of trade. Monisha Varadan of leading IPO website had suggested that the shares were overvalued. The alternative drugs company, which specialises in Chinese botanical medicine, raised 3.65 million pounds through a placing at 77p a share. Allnewissues said that Ofex-listed stock China Biotech was much cheaper. With warrants over 7 million shares, all of which are in the money, Phynova continues to look overcooked
Note their Scientific adviser: Brian Whittle PhD, Scientific Director, GW Pharmaceuticals plc Brian has over 40 years' experience in the pharmaceutical industry and was co-founder of Phytopharm and GW Pharmaceuticals plc
Agree, I put Mkt cap of £10.7m above for China Biotech, now edited....of course should read £4.7m
According to Ofex China Biotech mkt cap £4.7m and profitable.In my opinion a much better investment.
circa 7 million warrants 'in the money' with Phynova too! China Biotech far better value at this stage.
From all new issues: "There is a temptation to immediately compare this company to OFEX traded China Biotech. A company involved in a similar line of business, though one that is actually run by Chinese botanical medicinal experts". "Though the OFEX traded company clearly wins on financials as it is not only profitable, but growing fast. Financials for Phynova for the 15 months to 30th September saw losses of £606,653 racked up."
Chat Pages: 1
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180122 02:46:06